Ken Griffin Summit Therapeutics Inc. Call Options Transaction History

Citadel Advisors LLC

  • $509 Billion
  • Q1 2024

Call Options

5 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

May 15, 2024
BUY
$2.55 - $5.07 $19,380 - $38,532
7,600 Added 48.1%
23,400 $96,000
Q4 2023

Feb 14, 2024
BUY
$1.67 - $2.83 $26,386 - $44,714
15,800 New
15,800 $41,000
Q1 2023

May 15, 2023
SELL
$1.38 - $5.41 $93,702 - $367,339
-67,900 Reduced 87.5%
9,700 $16,000
Q4 2022

Feb 14, 2023
BUY
$0.68 - $5.31 $34,884 - $272,403
51,300 Added 195.06%
77,600 $329,000
Q3 2022

Nov 14, 2022
SELL
$0.89 - $1.63 $26,166 - $47,922
-29,400 Reduced 52.78%
26,300 $31,000

Others Institutions Holding SMMT

# of Institutions
107
Shares Held
41.3M
Call Options Held
103K
Put Options Held
29.9K
View Full List

About Summit Therapeutics Inc.

SMMT Quotes by TradingView
  • Ticker SMMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 201,215,008
  • Market Cap $1.52B
  • Description
  • Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...
More about SMMT
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email